Filing Details

Accession Number:
0001209191-16-108931
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-16 18:31:43
Reporting Period:
2016-03-14
Filing Date:
2016-03-16
Accepted Time:
2016-03-16 18:31:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
949858 Oncogenex Pharmaceuticals Inc. OGXI In Vitro & In Vivo Diagnostic Substances (2835) 954343413
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1229762 Cindy Jacobs 19820 North Creek Parkway, Suite 201
Bothell WA 98011
Evp, Cmo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-03-14 12,188 $0.00 77,107 No 4 M Direct
Common Stock Disposition 2016-03-15 3,254 $0.83 73,853 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Disposition 2016-03-14 1,875 $0.00 1,875 $0.00
Common Stock Restricted Stock Unit (RSU) Disposition 2016-03-14 2,500 $0.00 2,500 $0.00
Common Stock Restricted Stock Unit (RSU) Disposition 2016-03-14 3,125 $0.00 9,375 $0.00
Common Stock Restricted Stock Unit (RSU) Disposition 2016-03-14 4,688 $0.00 4,688 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2016-03-14 135,000 $0.00 135,000 $0.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-04-13 No 4 M Direct
2,500 2017-01-31 No 4 M Direct
6,250 2018-04-13 No 4 M Direct
14,062 2019-06-18 No 4 M Direct
135,000 2026-03-14 No 4 A Direct
Footnotes
  1. Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
  2. Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
  3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
  4. Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest on the later of: (i) each anniversary of January 1, 2012; and (ii) the first day thereafter during which the issuer's trading window is open.
  5. Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.
  6. Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2014; and (ii) the first day thereafter during which the issuer's trading window is open.
  7. Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015; and (ii) the first day thereafter during which the issuer's trading window is open.
  8. Pursuant to the terms of the options, 50% of the total shares underlying the option vest on the achievement of certain milestones, and 50% vest in monthly installments over 24 months commencing one month from achievement of one of the milestones. The options will lapse in full if achievement of one of the milestones is not met on or before December 31, 2016.